Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hAECs for Prevention of Acute GVHD After HSCT
NCT03764228Phase 1Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human amniotic epithelial stem cells in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Peking University People's Hospital. Primary endpoint: Occurrence of adverse events at 1 year. Status: unknown.
02
Drugs
human amniotic epithelial stem cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03764228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764228.